312 related articles for article (PubMed ID: 34396181)
1. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting.
Moey MYY; Tomdio AN; McCallen JD; Vaughan LM; O'Brien K; Naqash AR; Cherry C; Walker PR; Carabello BA
JACC CardioOncol; 2020 Sep; 2(3):491-502. PubMed ID: 34396256
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022.
Wu S; Bai H; Zhang L; He J; Luo X; Wang S; Fan G; Sun N
Front Cardiovasc Med; 2022; 9():969942. PubMed ID: 36035942
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study.
Zheng Y; Chen Z; Song W; Xu Y; Zhao Z; Sun Y; Wang Y; Geng X; Zhao J; Zhang X; Xu Y; Chan JSK; Tse G; Li G; Hong L; Liu T
Cancer Med; 2024 May; 13(10):e7233. PubMed ID: 38752474
[TBL] [Abstract][Full Text] [Related]
6. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Rini BI; Moslehi JJ; Bonaca M; Schmidinger M; Albiges L; Choueiri TK; Motzer RJ; Atkins MB; Haanen J; Mariani M; Wang J; Hariharan S; Larkin J
J Clin Oncol; 2022 Jun; 40(17):1929-1938. PubMed ID: 35239416
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor-associated myocarditis.
Zhao SH; Yun H; Chen CZ; Chen YY; Lin JY; Zeng MS; Liu TS; Pan CZ; Jin H
Eur Radiol; 2022 Nov; 32(11):7657-7667. PubMed ID: 35567603
[TBL] [Abstract][Full Text] [Related]
8. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Lehmann LH; Heckmann MB; Bailly G; Finke D; Procureur A; Power JR; Stein F; Bretagne M; Ederhy S; Fenioux C; Hamwy O; Funck-Brentano E; Romano E; Pieroni L; Münster JP; Allenbach Y; Anquetil C; Leonard-Louis S; Palaskas NL; Hayek SS; Katus HA; Giannitsis E; Frey N; Kaya Z; Moslehi J; Prifti E; Salem JE
Circulation; 2023 Aug; 148(6):473-486. PubMed ID: 37317858
[TBL] [Abstract][Full Text] [Related]
9. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events after the initiation of immune checkpoint inhibitors.
Suzuki Y; Kaneko H; Tamura Y; Okada A; Fujiu K; Michihata N; Takeda N; Jo T; Morita H; Node K; Yasunaga H; Komuro I
Heliyon; 2023 May; 9(5):e16373. PubMed ID: 37251893
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors.
Waissengein B; Abu Ata B; Merimsky O; Shamai S; Wolf I; Arnold JH; Bar-On T; Banai S; Khoury S; Laufer-Perl M
Clin Res Cardiol; 2023 Mar; 112(3):409-418. PubMed ID: 36301334
[TBL] [Abstract][Full Text] [Related]
13. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis.
Awadalla M; Mahmood SS; Groarke JD; Hassan MZO; Nohria A; Rokicki A; Murphy SP; Mercaldo ND; Zhang L; Zlotoff DA; Reynolds KL; Alvi RM; Banerji D; Liu S; Heinzerling LM; Jones-O'Connor M; Bakar RB; Cohen JV; Kirchberger MC; Sullivan RJ; Gupta D; Mulligan CP; Shah SP; Ganatra S; Rizvi MA; Sahni G; Tocchetti CG; Lawrence DP; Mahmoudi M; Devereux RB; Forrestal BJ; Mandawat A; Lyon AR; Chen CL; Barac A; Hung J; Thavendiranathan P; Picard MH; Thuny F; Ederhy S; Fradley MG; Neilan TG
J Am Coll Cardiol; 2020 Feb; 75(5):467-478. PubMed ID: 32029128
[TBL] [Abstract][Full Text] [Related]
14. Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy.
Lee C; Drobni ZD; Zafar A; Gongora CA; Zlotoff DA; Alvi RM; Taron J; Rambarat PK; Schoenfeld S; Mosarla RC; Raghu VK; Hartmann SE; Gilman HK; Murphy SP; Sullivan RJ; Faje A; Hoffmann U; Zhang L; Mayrhofer T; Reynolds KL; Neilan TG
JACC CardioOncol; 2022 Dec; 4(5):660-669. PubMed ID: 36636443
[TBL] [Abstract][Full Text] [Related]
15. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
[TBL] [Abstract][Full Text] [Related]
16. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors.
Laenens D; Yu Y; Santens B; Jacobs J; Beuselinck B; Bechter O; Wauters E; Staessen J; Janssens S; Van Aelst L
J Clin Oncol; 2022 Oct; 40(29):3430-3438. PubMed ID: 35772044
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
19. Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Isawa T; Toi Y; Sugawara S; Taguri M; Toyoda S
Oncologist; 2022 May; 27(5):e410-e419. PubMed ID: 35348766
[TBL] [Abstract][Full Text] [Related]
20. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
